CSPG4 and neoplasm: To decrease the possibility of on-target/off-tumour toxicity, one group combined a low-affinity CSPG4-CAR (225.28 clone-derived scFv linked to an IgG4 Fc region) with a chimeric co-stimulatory co-receptor (CCR) directed at CD20.